VOICE (MTN-003) IT S ALL ABOUT THE ENDPOINTS. Edward Livant MT (ASCP), MPH University of Pittsburgh Medical Center MTN Network Laboratory

Similar documents
9.1 Overview and General Guidance This section contains information on the laboratory procedures performed in MTN-035.

HOPE Follow-Up Algorithm: Unusual Cases. Urvi Parikh, PhD MTN Virology Core Regional Meeting Lab Breakout Sept 27-28, 2016, Cape Town

MTN 009 Laboratory Logistics

MTN-038 Laboratory Training. May Beamer, Michele Austin MTN Laboratory Center Magee-Womens Research Institute Pittsburgh, PA

QA Processes That Work: Minimizing Errors During On-site Rapid HIV Testing

Investigating Unresolved HIV Status during Endpoint Confirmation. Kristen Cummings MTN Virology CORE

MTN 015 SPECIMEN REVIEW. Gabriel Banda Core Lab Supervisor UNC Project, Lilongwe

MTN 005 Laboratory Training. Lorna Rabe MTN Network Laboratory Magee-Womens Research Institute Pittsburgh, PA

Section 6. Participant Follow-up

Section 9. Laboratory Considerations

Follow-up Visit Procedures MTN-009

Section 5. Study Procedures

Section 6. Participant Follow-up

Section 12. Laboratory Considerations

Section 13. Laboratory Considerations

Pregnancy Testing Concerns The Ides of March: Et Tu, Quidel? Edward Livant BS, MPH MTN Laboratory Center

SCREENING AND ENROLLMENT CONSIDERATIONS MTN-038 STUDY-SPECIFIC TRAINING

MTN 003 MONTHS 1 & 2 VISIT PRESENTATION ZIMBABWE TEAM JULIET MOYO RESEARCH NURSE MARTHA MASAWI COUNSELLOR

ENHANCING LAB PERFORMANCE

Section 5. Study Procedures

HPTN 035. Laboratory Overview

Specimen Management PHRU LAB

Section 6. Participant Follow-up

VOICE Screening Part 1 Visit. Operational Walkthrough Johannesburg, South Africa November 2008

MTN-038 Clinical Considerations. Site Specific Training 11 Sept 2018

Section 9 Laboratory Consideration

Section 5. Study Procedures

Overview of Enrollment/Initiate Period 1 Visit Procedures

GSK , 2.0, 18, 2014, DAIDS

Prior to site activation the following events were lined up

HIV Update in Laboratory Testing. Patricia Slev, PhD, D(ABCC)

HIV Screening & Consent for Testing

Module 3: Overview of HIV Testing Technologies

Section 10. Counseling Procedures

2018 HIV and HCV Diagnostic Testing Survey

Section 11. Counseling Procedures

Section 10 Counseling Considerations

Supplementary Online Content

HEALTH. Re: Interim Guidelines for Laboratories on the use of a new Diagnostic Testing Algorithm for Human Immunodeficiency Virus (HIV) Infection

Epidemiologists and Laboratory Science

APHL/CDC HIV Demonstration Project Demonstration Project for HIV Nucleic Acid Testing (NAT) Referral Updated: January 2018

Quicker, Better, Faster Optimising Turn Around Time of Laboratory Results

Section 9. Laboratory Considerations

SUMMARY OF CHANGES INCLUDED IN THE FULL PROTOCOL AMENDMENT OF: MTN-004 DAIDS Document ID 10492

Adverse Event Monitoring and Reporting

The Kisumu Clinical Research Site. Mumbi Makanga MBChB, MPH MTN Regional Meeting 28 th September 2016

Adventures in Discordance- HIV Testing

Technical Bulletin No. 104b

FDA Reentry Guidance

Section 9. Laboratory Considerations

Rapid testing algorithm performance in a low prevalence environment: NJ

Section 8. Clinical Considerations

ANTIBODY SCREENING by Uni-Gold Recombigen HIV

Case Studies, or Verification Vignettes

HVTN HIV Diagnostics Program

Diagnosis and Management of Acute HIV

HIV Test Technologies, Best Practices, and New Algorithm. Jenny R. McFarlane DSHS HIV Prevention and Care Branch

Draft Report WHO evaluation of HIV 1/2 STAT-PAK (Chembio Diagnostic Systems Inc)

HIV Serology Quality Assessment Program Summary for Panel HIVSER 2017Apr19

Technical Bulletin No. 104a

The laboratory preparation for a new study a pragmatic approach. Compiled by Ken Clarke and Lindiwe Nhlangulela October 2011

Demographics. 2. What was your sex at birth? If female, participant is ineligible. End of form.

Letter of Amendment # 3 to:

The Feasibility of HIV Prevention Cohort Studies among Men who have Sex with Men (MSM) in sub-saharan Africa

MedDRA Coding/ AE Log Item 1 Refresher. ASPIRE Protocol Team Meeting February 10, 2013

HIV Serology Quality Assessment Program Summary for Panel HIVSER 2018Apr19

An Update on FACTS 001. Prof Helen Rees FACTS Protocol Chair

Overview of Wet Preps and Gram stains. Lorna Rabe Central Lab Magee-Womens Research Institute Pittsburgh, Pa

HCV Testing Challenges & Systems-based Solutions

The Promise of HIV Prevention in Pregnancy. Richard H. Beigi, MD., MSc. University of Pittsburgh Pittsburgh, PA USA

ACTG Laboratory Technologist Committee Revised Version 2.0 ACTG Lab Man Coulter HIV-1 p24 ELISA May 21, 2004

URGENT FIELD SAFETY NOTICE - EXPANSION

Sexually Transmi/ed Diseases

Potential Effect of Alternative HIV Testing Algorithms on HIV Case Surveillance

If the HPTN 082 protocol is amended in the future, this Letter of Amendment will be incorporated into the next version.

The HIV Bridge Algorithm: Linking Point-of-Contact, Laboratory and Patient Care HIV Diagnostic Conference March 24, 2010

HIV Diagnostic Testing

WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT. Product: Alere HIV Combo WHO reference number: PQDx

MTN-038 SSP Manual Version November 2018 Section 10 Page 10-1 of 10-30

MTN-020 and IPM 027 and the MTN-020 DSMB. Jared Baeten, MD PhD Thesla Palanee, PhD ASPIRE Protocol Team Meeting 22 February 2012

LETTER OF AMENDMENT #2 TO: MTN-036/IPM 047. A Phase 1, Randomized Pharmacokinetics and Safety Study of Extended Duration Dapivirine Vaginal Rings

A Summary of Clinical Evidence

4. RED AND BLUE TOP COLLECTION SWABS WILL NO LONGER BE SUPPLIED FOR BACTERIAL CULTURE

WHO Prequalification of In Vitro Diagnostics PUBLIC REPORT. Product: DPP HIV 1/2 Assay WHO reference number: PQDx

ONLINE SUPPLEMENTARY MATERIALS: FILE 1

Contraceptive Research and Development Organization

HIV Testing Technology and the Latest Algorithm

Guidelines for HIV Rapid Test Kits Evaluation

Integrating HIV Screening Into

TAP HERE TO SEE THE PRODUCT

Standard Operating Procedure

MTN-026 Clinical Management Overview

TEST REQUEST INFORMATION- VIROLOGY

Minimum Standards for Laboratories in SADC Regions

Learning Objectives. New HIV Testing Algorithm from CDC. Overview of HIV infection and disease 3/15/2016

Section 10. Laboratory Considerations

QUESTIONS AND ANSWERS ABOUT PARTNERS PrEP AND VOICE

Transcription:

VOICE (MTN-003) IT S ALL ABOUT THE ENDPOINTS Edward Livant MT (ASCP), MPH University of Pittsburgh Medical Center MTN Network Laboratory

Review of Sample 2

Testing starts here with rapid test (s). Negative Stop Positive Continue Discordant Continue

If you had a positive rapid test, you will perform a Western Blot. This is Sample 1 If the results are negative or Indeterminate, proceed to an RNA. Sites can consider a positive HIV rapid test indication to store plasma archive if possible. This is not a requirement. If the results are positive, proceed to sample 2.

If the RNA is Positive, proceed to sample 2. If the sample is negative, the algorithm is complete. We suggest you contact the Network Laboratory or protocol team in this situation for guidance.

If the Sample 2 Western Blot is negative or indeterminate, contact the MTN Network Laboratory for guidance. If the Sample 2 Western Blot is positive, local HIV diagnostic testing is complete. The Network Laboratory will do a third confirmatory test.

Know the differences: Sample 1 versus Sample 2 What triggers a sample 2?. Positive HIV rapid test with a positive HIV Western Blot Sample 2 requires collection of additional specimens. Use the Sample 2 checklist.

The checklist shows what specimens are needed at Sample 2: Western Blot Plasma archive CD4 HIV RNA

Specimen Collection at Sample 2 Specimens Required at Sample 2 Plasma Archive Must store minimum 6 ml of plasma; draw 12-15 ml of whole blood Local Testing-draw amounts vary with site criteria CD4 Count RNA HIV-1 Viral Load HIV-1 Western Blot

Importance of Plasma archive Enrollment plasma archive and Sample 2 plasma archive have an even higher importance then routine visit archives Why?

Importance of Plasma archive Enrollment plasma archive and Sample 2 plasma archive have an even higher importance then routine visit archives Why? Plasma archive from enrollment shows that the participant was uninfected at enrollment. It is the only archive sample before the participant is on product.

Importance of Plasma archive Enrollment plasma archive and Sample 2 plasma archive have an even higher importance then routine visit archives Why? Sample 2 archive may help give a better idea of when infection occurred.

Importance of Plasma archive Enrollment plasma archive and Sample 2 plasma archive have an even higher importance then routine visit archives Why? Sample 2 archive is usually the earliest plasma available for resistance testing after infection. Resistance patterns can change over time.

Importance of Plasma archive Enrollment plasma archive and Sample 2 plasma archive have an even higher importance then routine visit archives Why? The plasma from enrollment and sample 2 are crucial to verify true endpoints.

Specimen Collection at Sample 2 and Enrollment If there is a problem with these plasma archives (missed, lost, sample damaged, etc..) You do not need to wait for permission from the NL or protocol team to call back participant Notify the NL or protocol team immediately to report problem and get guidance on documentation. These are the most precious samples in VOICE.

Additional Topics

Urine Dipstick Discussion Any Siemens dipstick can be used-the tests in the different combinations (4, 9) are the same. Any abnormal results on dipsticks should trigger participant follow up, even if not a protocol analyte for VOICE. (Bilirubin, Blood, etc ) Should all sites consider using the 4 test strip?

Operational Reminders From NL LDMS Reconciliations-why do I have to fix these CRF s? Because this will be the only way to resolve the errors and have correct data at SCHARP. DAIDS requires you run QC at least once per week for rapid tests if you test participants that week.

Operational Reminders From NL Make sure to use the Quidel Urine Pregnancy Kit. Do not use the Urine + Serum combo kit. Why? Because the combo kit has not been validated for use with vaginal gels. The urine kit has been validated for use with gels.

Examples of Emerging Issues Issue: Staff omitted RNA viral load from follow up algorithm Response: Make sure staff review algorithm frequently and note differences between screening and follow up

Examples of Emerging Issues Issue: Staff did not take swabs for storage during a pelvic exam Response: Review procedures for the sample collection required during pelvic exams

Examples of Emerging Issues Issue: Repeat labs missed. Response: Make sure to review procedures for when to repeat tests

Examples of Emerging Issues Issue: Missed plasma archive enrollment Response: Make all efforts possible to get enrollment archive samples. These are very precious because they cannot be truly recollected after the participant has started product. If it is missed or there is a problem in processing, recollect as soon as possible.

Examples of Emerging Issues Issue: Specimens collected outside the office at a home and a workplace. Response: Specimens cannot be collected outside of the clinic.

Examples of Emerging Issues Issue: Participant enrolled who had exclusionary lab results Response: Add additional reviews if necessary

Examples of Emerging Issues What do these examples teach us? Review the checklists prior to participant visits. Review procedures frequently.

Thank You-Questions?